Skip to main content
SpringerLink
Log in

Cannabinoid-Opioid Interactions

  • Chapter
  • First Online:
Cannabinoid Modulation of Emotion, Memory, and Motivation

Abstract

The growing use of cannabis in western societies is of significant concern especially considering that its consumption has increased in teens who are most at risk for developing addictive disorders and other psychiatric illnesses linked to early cannabis exposure. Unfortunately recent years have also seen a surge in the abuse of opioid drugs, a phenomenon often predated by early cannabis use. Moreover, many abusers find greater reward by combining use of cannabis with opioids such as heroin. These patterns suggest possible synergistic interactions between cannabinoid and opioid systems underlying addiction and related psychiatric disorders. This chapter reviews neurobiological systems relevant to reward, motivation and emotional regulation in which cannabinoids and opioids interact.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future national results on drug use: 2012 Overview, Key Findings on Adolescent Drug Use. Institute for Social Research, The University of Michigan. Ann Arbor. 2013.

    Google Scholar 

  2. SAMHSA. Results from the 2012 National Survey on Drug Use and Health: summary of National Findings. Substance Abuse and Mental Health Services Administration, Rockville, MD. 2013.

    Google Scholar 

  3. EMCDDA. Annual report on the state of the drugs problem in Europe. Publications Office of the European Union, Luxembourg; 2012.

    Google Scholar 

  4. Lynskey MT, Heath AC, Bucholz KK, Slutske WS, Madden PA, Nelson EC, Statham DJ, Martin NG. Escalation of drug use in early-onset cannabis users vs co-twin controls. JAMA. 2003;289(4):427–33.

    Article  PubMed  Google Scholar 

  5. Fergusson DM, Horwood LJ. Does cannabis use encourage other forms of illicit drug use? Addiction. 2000;95(4):505–20.

    Article  CAS  PubMed  Google Scholar 

  6. Agrawal A, Neale MC, Prescott CA, Kendler KS. A twin study of early cannabis use and subsequent use and abuse/dependence of other illicit drugs. Psychol Med. 2004;34(7):1227–37.

    Article  PubMed  Google Scholar 

  7. Spano MS, Fadda P, Fratta W, Fattore L. Cannabinoid-opioid interactions in drug discrimination and self-administration: effect of maternal, postnatal, adolescent and adult exposure to the drugs. Curr Drug Targets. 2010;11(4):450–61.

    Article  CAS  PubMed  Google Scholar 

  8. Morris CV, DiNieri JA, Szutorisz H, Hurd YL. Molecular mechanisms of maternal cannabis and cigarette use on human neurodevelopment. Eur J Neurosci. 2011;34(10):1574–83.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Chadwick B, Miller ML, Hurd YL. Cannabis use during adolescent development: susceptibility to psychiatric illness. Front Psychiatry. 2013;4:129.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Bluelight.org. Forum on “Cannabis action on opioid receptors”, Cannabis Discussion Forum. http://www.bluelight.org/vb/archive/index.php/t-455925.html (2009). Accessed Jan 2014.

  11. Navarro M, Carrera MRA, Fratta W, Valverde O, Cossu G, Fattore L, Chowen JA, Gomez R, del Arco I, Villanua MA, Maldonado R, Koob GF, de Fonseca FR. Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci. 2001;21(14):5344–50.

    CAS  PubMed  Google Scholar 

  12. Cossu G, Ledent C, Fattore L, Imperato A, Bohme GA, Parmentier M, Fratta W. Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav Brain Res. 2001;118(1):61–5.

    Article  CAS  PubMed  Google Scholar 

  13. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science. 1999;283(5400):401–4.

    Article  CAS  PubMed  Google Scholar 

  14. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. Eur J Neurosci. 2000;12(11):4038–46.

    Google Scholar 

  15. Ellgren M, Spano SM, Hurd YL. Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. Neuropsychopharmacology. 2007;32(3):607–15.

    Article  CAS  PubMed  Google Scholar 

  16. Tomasiewicz HC, Jacobs MM, Wilkinson MB, Wilson SP, Nestler EJ, Hurd YL. Proenkephalin mediates the enduring effects of adolescent cannabis exposure associated with adult opiate vulnerability. Biol Psychiatry. 2012;72(10):803–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Solinas M, Panlilio LV, Goldberg SR. Exposure to ∆9-tetrahydrocannabinol (THC) increases subsequent heroin taking but not heroin’s reinforcing efficacy: a self-administration study in rats. Neuropsychopharmacology. 2004;29(7):1301–11.

    Article  CAS  PubMed  Google Scholar 

  18. Singh ME, McGregor IS, Mallet PE. Perinatal exposure to ∆9-Tetrahydrocannabinol alters heroin-induced place conditioning and fos-immunoreactivity. Neuropsychopharmacology. 2006;31(1):58–69.

    CAS  PubMed  Google Scholar 

  19. Biscaia M, Fernandez B, Higuera-Matas A, Miguens M, Viveros MP, Garcia-Lecumberri C, Ambrosio E. Sex-dependent effects of periadolescent exposure to the cannabinoid agonist CP-55,940 on morphine self-administration behaviour and the endogenous opioid system. Neuropharmacology. 2008;54(5):863–73.

    Article  CAS  PubMed  Google Scholar 

  20. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A. 1990;87(5):1932–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Westlake TM, Howlett AC, Bonner TI, Matsuda LA, Herkenham M. Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer’s brains. Neuroscience. 1994;63(3):637–52.

    Article  CAS  PubMed  Google Scholar 

  22. den Boon FS, Chameau P, Schaafsma-Zhao Q, van Aken W, Bari M, Oddi S, Kruse CG, Maccarrone M, Wadman WJ, Werkman TR. Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors. Proc Natl Acad Sci U S A. 2012;109(9):3534–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Cabral GA, Raborn ES, Griffin L, Dennis J, Marciano-Cabral F. CB2 receptors in the brain: role in central immune function. Br J Pharmacol. 2008;153(2):240–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Brusco A, Tagliaferro PA, Saez T, Onaivi ES. Ultrastructural localization of neuronal brain CB2 cannabinoid receptors. Ann NY Acad Sci. 2008;1139:450–7.

    Article  CAS  PubMed  Google Scholar 

  25. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev. 2003;83(3):1017–66.

    Article  CAS  PubMed  Google Scholar 

  26. Hillard CJ, Campbell WB. Biochemistry and pharmacology of arachidonylethanolamide, a putative endogenous cannabinoid. J Lipid Res. 1997;38(12):2383–98.

    CAS  PubMed  Google Scholar 

  27. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, Matias I, Schiano-Moriello A, Paul P, Williams EJ, Gangadharan U, Hobbs C, Di Marzo V, Doherty P. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol. 2003;163(3):463–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 1996;384(6604):83–7.

    Article  CAS  PubMed  Google Scholar 

  29. Dinh TP, Freund TF, Piomelli D. A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids. 2002;121(1–2):149–58.

    Article  CAS  PubMed  Google Scholar 

  30. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A. 2002;99(16):10819–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Gulyas AI, Cravatt BF, Bracey MH, Dinh TP, Piomelli D, Boscia F, Freund TF. Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci. 2004;20(2):441–58.

    Article  CAS  PubMed  Google Scholar 

  32. De Carvalho CR, Pamplona FA, Cruz JS, Takahashi RN. Endocannabinoids underlie reconsolidation of hedonic memories in Wistar rats. Psychopharmacology (Berl). 2013;231(7):1417–25.

    Article  Google Scholar 

  33. Akil H, Watson SJ, Young E, Lewis ME, Khachaturian H, Walker JM. Endogenous opioids: biology and function. Annu Rev Neurosci. 1984;7:223–55.

    Article  CAS  PubMed  Google Scholar 

  34. Calò G, Lambert DG, Guerrini R. Chapter 215—Nociceptin/Orphanin FQ. In: Kastin AJ, editor. Handbook of biologically active peptides. 2nd edn. Boston: Academic; 2013. pp. 1577–1585.

    Chapter  Google Scholar 

  35. Bals-Kubik R, Ableitner A, Herz A, Shippenberg TS. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J Pharmacol Exp Ther. 1993;264(1):489–95.

    CAS  PubMed  Google Scholar 

  36. Shippenberg TS, Bals-Kubik R, Herz A. Motivational properties of opioids: evidence that an activation of δ-receptors mediates reinforcement processes. Brain Res. 1987;436(2):234–9.

    Article  CAS  PubMed  Google Scholar 

  37. Pfeiffer A, Brandt V, Herz A. Psychotomimesis mediated by κ opiate receptors. Science. 1986;233:774–6.

    Article  CAS  PubMed  Google Scholar 

  38. Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, Maldonado R. Motivational effects of cannabinoids are mediated by μ-opioid and κ-opioid receptors. J Neurosci. 2002;22(3):1146–54.

    CAS  PubMed  Google Scholar 

  39. Valverde O, Noble F, Beslot F, Dauge V, Fournie-Zaluski MC, Roques BP. ∆9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. Eur J Neurosci. 2001;13(9):1816–24.

    Article  CAS  PubMed  Google Scholar 

  40. Koob GF. Neural mechanisms of drug reinforcement. Ann NY Acad Sci. 1992;654:171–91.

    Article  CAS  PubMed  Google Scholar 

  41. Everitt BJ, Wolf ME. Psychomotor stimulant addiction: a neural systems perspective. J Neurosci. 2002;22(9):3312–20.

    CAS  PubMed  Google Scholar 

  42. Haber SN, Fudge JL. The primate substantia nigra and VTA: integrative circuitry and function. Crit Rev Neurobiol. 1997;11(4):323–42.

    Article  CAS  PubMed  Google Scholar 

  43. Le Moine C, Normand E, Bloch B. Phenotypical characterization of the rat striatal neurons expressing the D1 dopamine receptor gene. Proc Natl Acad Sci U S A. 1991;88:4205–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Le Moine C, Normand E, Guitteny AF, Fouque B, Teoule R, Bloch B. Dopamine receptor gene expression by enkephalin neurons in rat forebrain. Proc Natl Acad Sci U S A. 1990;87(1):230–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Gerfen CR, Enber TM, Susel Z, Chase TN, Monsma FJ, Mahan LC, Sibley DR. D1 and D2 dopamine receptor regulated gene expression of striatonigral and striatopallidal neurons. Science. 1990;250:1429–32.

    Article  CAS  PubMed  Google Scholar 

  46. Brownstein MJ, Mroz EA, Tappaz ML, Leeman SE. On the origin of substance P and glutamic acid decarboxylase (GAD) in the substantia nigra. Brain Res. 1977;135(2):315–23.

    Article  CAS  PubMed  Google Scholar 

  47. Vincent SR, Hokfelt T, Christensson I, Terenius L. Dynorphin-immunoreactive neurons in the central nervous system of the rat. Neurosci Lett. 1982;33(2):185–90.

    Article  CAS  PubMed  Google Scholar 

  48. Cuello AC, Paxinos G. Evidence for a long Leu-enkephalin striopallidal pathway in rat brain. Nature. 1978;271(5641):178–80.

    Article  CAS  PubMed  Google Scholar 

  49. Zhou L, Furuta T, Kaneko T. Chemical organization of projection neurons in the rat accumbens nucleus and olfactory tubercle. Neuroscience. 2003;120(3):783–98.

    Article  CAS  PubMed  Google Scholar 

  50. Durieux PF, Bearzatto B, Guiducci S, Buch T, Waisman A, Zoli M, Schiffmann SN, de Kerchove d’Exaerde A. D2R striatopallidal neurons inhibit both locomotor and drug reward processes. Nat Neurosci. 2009;12(4):393–5.

    Article  CAS  PubMed  Google Scholar 

  51. Frank MJ, Moustafa AA, Haughey HM, Curran T, Hutchison KE. Genetic triple dissociation reveals multiple roles for dopamine in reinforcement learning. Proc Natl Acad Sci U S A. 2007;104(41):16311–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Klein TA, Neumann J, Reuter M, Hennig J, von Cramon DY, Ullsperger M. Genetically determined differences in learning from errors. Science. 2007;318(5856):1642–5.

    Article  CAS  PubMed  Google Scholar 

  53. Sano H, Yasoshima Y, Matsushita N, Kaneko T, Kohno K, Pastan I, Kobayashi K. Conditional ablation of striatal neuronal types containing dopamine D2 receptor disturbs coordination of basal ganglia function. J Neurosci. 2003;23(27):9078–88.

    CAS  PubMed  Google Scholar 

  54. Lobo MK, Covington HE 3rd, Chaudhury D, Friedman AK, Sun H, Damez-Werno D, Dietz DM, Zaman S, Koo JW, Kennedy PJ, Mouzon E, Mogri M, Neve RL, Deisseroth K, Han MH, Nestler EJ. Cell type-specific loss of BDNF signaling mimics optogenetic control of cocaine reward. Science. 2010;330(6002):385–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Rodriguez JJ, Mackie K, Pickel VM. Ultrastructural localization of the CB1 cannabinoid receptor in μ-opioid receptor patches of the rat Caudate Putamen nucleus. J Neurosci. 2001;21:823–33.

    CAS  PubMed  Google Scholar 

  56. Pickel VM, Chan J, Kash TL, Rodriguez JJ, MacKie K. Compartment-specific localization of cannabinoid 1 (CB1) and μ-opioid receptors in rat nucleus accumbens. Neuroscience. 2004;127(1):101–12.

    Article  CAS  PubMed  Google Scholar 

  57. Canals M, Milligan G. Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed Mu opioid receptors. J Biol Chem. 2008;283(17):11424–34.

    Article  CAS  PubMed  Google Scholar 

  58. Blume LC, Bass CE, Childers SR, Dalton GD, Roberts DC, Richardson JM, Xiao R, Selley DE, Howlett AC. Striatal CB1 and D2 receptors regulate expression of each other, CRIP1A and delta opioid systems. J Neurochem. 2013;124(6):808–20.

    Article  CAS  PubMed  Google Scholar 

  59. Glass M, Felder CC. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci. 1997;17(14):5327–33.

    CAS  PubMed  Google Scholar 

  60. Kearn CS, Blake-Palmer K, Daniel E, Mackie K, Glass M. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol Pharmacol. 2005;67(5):1697–704.

    Article  CAS  PubMed  Google Scholar 

  61. Jarrahian A, Watts VJ, Barker EL. D2 dopamine receptors modulate Gα-subunit coupling of the CB1 cannabinoid receptor. J Pharmacol Exp Ther. 2004;308(3):880–6.

    Article  CAS  PubMed  Google Scholar 

  62. Rios C, Gomes I, Devi LA. μ opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol. 2006;148(4):387–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Hurd YL, Herkenham M. The human neostriatum shows compartmentalization of neuropeptide gene expression in dorsal and ventral regions: an in situ hybridization histochemical analysis. Neuroscience. 1995;64(3):571–86.

    Article  CAS  PubMed  Google Scholar 

  64. Guttenberg ND, Klop H, Minami M, Satoh M, Voorn P. Co-localization of μ opioid receptor is greater with dynorphin than enkephalin in rat striatum. Neuroreport. 1996;7(13):2119–24.

    Article  CAS  PubMed  Google Scholar 

  65. Pugh G Jr, Abood ME, Welch SP. Antisense oligodeoxynucleotides to the κ-1 receptor block the antinociceptive effects of ∆9-THC in the spinal cord. Brain Res. 1995;689(1):157–8.

    Article  CAS  PubMed  Google Scholar 

  66. Pugh G Jr, Smith PB, Dombrowski DS, Welch SP. The role of endogenous opioids in enhancing the antinociception produced by the combination of ∆9-tetrahydrocannabinol and morphine in the spinal cord. J Pharmacol Exp Ther. 1996;279(2):608–16.

    CAS  PubMed  Google Scholar 

  67. Pugh G Jr, Mason DJ Jr, Combs V, Welch SP. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord. J Pharmacol Exp Ther. 1997;281(2):730–7.

    CAS  PubMed  Google Scholar 

  68. Houser SJ, Eads M, Embrey JP, Welch SP. Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, ∆9-THC and anandamide. Brain Res. 2000;857(1–2):337–42.

    Google Scholar 

  69. Corchero J, Avila MA, Fuentes JA, Manzanares J. Δ-9-Tetrahydrocannabinol increases prodynorphin and proenkephalin gene expression in the spinal cord of the rat. Life Sci. 1997;61(4):PL 39–43.

    Article  Google Scholar 

  70. Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA, Fuentes JA. Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain. Brain Res Mol Brain Res. 1998;55(1):126–32.

    Article  CAS  PubMed  Google Scholar 

  71. Corchero J, Fuentes JA, Manzanares J. Δ9-Tetrahydrocannabinol increases proopiomelanocortin gene expression in the arcuate nucleus of the rat hypothalamus. Eur J Pharmacol. 1997;323(2–3):193–5.

    Article  CAS  PubMed  Google Scholar 

  72. Wang X, Dow-Edwards D, Anderson V, Minkoff H, Hurd YL. Discrete opioid gene expression impairment in the human fetal brain associated with maternal marijuana use. Pharmacogenomics J. 2006;6(4):255–64.

    PubMed  Google Scholar 

  73. Spano MS, Ellgren M, Wang X, Hurd YL. Prenatal cannabis exposure increases heroin seeking with allostatic changes in limbic enkephalin systems in adulthood. Biol Psychiatry. 2007;61(4):554–63.

    Article  CAS  PubMed  Google Scholar 

  74. Perez-Rosado A, Manzanares J, Fernandez-Ruiz J, Ramos JA. Prenatal ∆9-tetrahydrocannabinol exposure modifies proenkephalin gene expression in the fetal rat brain: sex-dependent differences. Brain Res Dev Brain Res. 2000;120(1):77–81.

    Article  CAS  PubMed  Google Scholar 

  75. Morel LJ, Giros B, Dauge V. Adolescent exposure to chronic delta-9-tetrahydrocannabinol blocks opiate dependence in maternally deprived rats. Neuropsychopharmacology. 2009;34(11):2469–76.

    Article  CAS  PubMed  Google Scholar 

  76. Corchero J, Garcia-Gil L, Manzanares J, Fernandez-Ruiz JJ, Fuentes JA, Ramos JA. Perinatal delta9-tetrahydrocannabinol exposure reduces proenkephalin gene expression in the caudate-putamen of adult female rats. Life Sci. 1998;63(10):843–50.

    Article  CAS  PubMed  Google Scholar 

  77. Corchero J, Romero J, Berrendero F, Fernandez-Ruiz J, Ramos JA, Fuentes JA, Manzanares J. Time-dependent differences of repeated administration with ∆9-tetrahydrocannabinol in proenkephalin and cannabinoid receptor gene expression and G-protein activation by μ-opioid and CB1-cannabinoid receptors in the caudate-putamen. Brain Res Mol Brain Res. 1999;67(1):148–57.

    Article  CAS  PubMed  Google Scholar 

  78. Heinz A, Siessmeier T, Wrase J, Hermann D, Klein S, Grusser SM, Flor H, Braus DF, Buchholz HG, Grunder G, Schreckenberger M, Smolka MN, Rosch F, Mann K, Bartenstein P. Correlation between dopamine D2 receptors in the ventral striatum and central processing of alcohol cues and craving. Am J Psychiatry. 2004;161(101927):1783–9.

    Article  PubMed  Google Scholar 

  79. Volkow ND, Chang L, Wang GJ, Fowler JS, Ding YS, Sedler M, Logan J, Franceschi D, Gatley J, Hitzemann R, Gifford A, Wong C, Pappas N. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry. 2001;158(12):2015–21.

    Article  CAS  PubMed  Google Scholar 

  80. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Gifford A, Hitzemann R, Ding YS, Pappas N. Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels. Am J Psychiatry. 1999;156(9):1440–3.

    CAS  PubMed  Google Scholar 

  81. Wang GJ, Volkow ND, Fowler JS, Logan J, Abumrad NN, Hitzemann RJ, Pappas NS, Pascani K. Dopamine D2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal. Neuropsychopharmacology. 1997;16:174–82.

    Article  CAS  PubMed  Google Scholar 

  82. Volkow ND, Fowler JS, Wang GJ, Swanson JM. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry. 2004;9(6):557–69.

    Article  CAS  PubMed  Google Scholar 

  83. Jutras-Aswad D, Jacobs MM, Yiannoulos G, Roussos P, Bitsios P, Nomura Y, Liu X, Hurd YL. Cannabis-dependence risk relates to synergism between neuroticism and proenkephalin snps associated with amygdala gene expression: case-control study. PLoS ONE. 2012;7(6):e39243.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Nikoshkov A, Drakenberg K, Wang X, Horvath MC, Keller E, Hurd YL. Opioid neuropeptide genotypes in relation to heroin abuse: dopamine tone contributes to reversed mesolimbic proenkephalin expression. Proc Natl Acad Sci U S A. 2008;105(2):786–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Gunduz-Cinar O, Hill MN, McEwen BS, Holmes A. Amygdala FAAH and anandamide: mediating protection and recovery from stress. Trends Pharmacol Sci. 2013;34(11):637–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Viveros MP, Marco EM, File SE. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav. 2005;81(2):331–42.

    Article  CAS  PubMed  Google Scholar 

  87. Katona I, Rancz EA, Acsady L, Ledent C, Mackie K, Hajos N, Freund TF. Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci. 2001;21(23):9506–18.

    CAS  PubMed  Google Scholar 

  88. McDonald AJ, Mascagni F. Localization of the CB1 type cannabinoid receptor in the rat basolateral amygdala: high concentrations in a subpopulation of cholecystokinin-containing interneurons. Neuroscience. 2001;107(4):641–52.

    Article  CAS  PubMed  Google Scholar 

  89. Marsicano G, Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci. 1999;11(12):4213–25.

    Article  CAS  PubMed  Google Scholar 

  90. Mansour A, Fox CA, Akil H, Watson SJ. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci. 1995;18(1):22–9.

    Article  CAS  PubMed  Google Scholar 

  91. Sar M, Stumpf WE, Miller RJ, Chang KJ, Cuatrecasas P. Immunohistochemical localization of enkephalin in rat brain and spinal cord. J Comp Neurol. 1978;182(1):17–37.

    Article  CAS  PubMed  Google Scholar 

  92. Veinante P, Stoeckel ME, Freund-Mercier MJ. GABA- and peptide-immunoreactivities co-localize in the rat central extended amygdala. Neuroreport. 1997;8(13):2985–9.

    Article  CAS  PubMed  Google Scholar 

  93. Erb S. Evaluation of the relationship between anxiety during withdrawal and stress-induced reinstatement of cocaine seeking. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(5):798–807.

    Article  CAS  PubMed  Google Scholar 

  94. Kung JC, Chen TC, Shyu BC, Hsiao S, Huang AC. Anxiety- and depressive-like responses and c-fos activity in preproenkephalin knockout mice: oversensitivity hypothesis of enkephalin deficit-induced posttraumatic stress disorder. J Biomed Sci. 2010;17:29.

    Article  PubMed  PubMed Central  Google Scholar 

  95. Jutras-Aswad D, DiNieri JA, Harkany T, Hurd YL. Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome. Eur Arch Psychiatry Clin Neurosci. 2009;259(7):395–412.

    Article  PubMed  Google Scholar 

  96. Fitzgerald ML, Shobin E, Pickel VM. Cannabinoid modulation of the dopaminergic circuitry: implications for limbic and striatal output. Prog Neuropsychopharmacol Biol Psychiatry. 2012;38(1):21–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Zahm DS, Jensen SL, Williams ES, Martin JR 3rd. Direct comparison of projections from the central amygdaloid region and nucleus accumbens shell. Eur J Neurosci. 1999;11(4):1119–26.

    Article  CAS  PubMed  Google Scholar 

  98. Fudge JL, Haber SN. The central nucleus of the amygdala projection to dopamine subpopulations in primates. Neuroscience. 2000;97(3):479–94.

    Article  CAS  PubMed  Google Scholar 

  99. Johnson SW, North RA. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci. 1992;12(2):483–8.

    CAS  PubMed  Google Scholar 

  100. Solinas M, Zangen A, Thiriet N, Goldberg SR. β-endorphin elevations in the ventral tegmental area regulate the discriminative effects of ∆9-tetrahydrocannabinol. Eur J Neurosci. 2004;19(12):3183–92.

    Article  CAS  PubMed  Google Scholar 

  101. Rashidy-Pour A, Pahlevani P, Vaziri A, Shaigani P, Zarepour L, Vafaei AA, Haghparast A. Involvement of CB1 receptors in the ventral tegmental area in the potentiation of morphine rewarding properties in acquisition but not expression in the conditioned place preference model. Behav Brain Res. 2013;247:259–67.

    Article  CAS  PubMed  Google Scholar 

  102. Singh ME, Verty AN, Price I, McGregor IS, Mallet PE. Modulation of morphine-induced Fos-immunoreactivity by the cannabinoid receptor antagonist SR 141716. Neuropharmacology. 2004;47(8):1157–69.

    Article  CAS  PubMed  Google Scholar 

  103. Fattore L, Vigano D, Fadda P, Rubino T, Fratta W, Parolaro D. Bidirectional regulation of mu-opioid and CB1-cannabinoid receptor in rats self-administering heroin or WIN 55,212-2. Eur J Neurosci. 2007;25(7):2191–200.

    Article  PubMed  Google Scholar 

  104. Allen K, McGregor IS, Hunt GE, Singh ME, Mallet PE. Regional differences in naloxone modulation of ∆9-THC induced Fos expression in rat brain. Neuropharmacology. 2003;44(2):264–74.

    Google Scholar 

  105. Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common μ1 opioid receptor mechanism. Science. 1997;276(5321):2048–50.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Neuroscience and Psychiatry, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Michael L. Miller, Benjamin Chadwick, Claudia V. Morris, Michael Michaelides & Yasmin L. Hurd

  2. Icahn School of Medicine at Mount Sinai, Hess Center for Science and Medicine, New York, NY, USA

    Yasmin L. Hurd

Authors
  1. Michael L. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Benjamin Chadwick
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Claudia V. Morris
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Michaelides
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yasmin L. Hurd
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yasmin L. Hurd .

Editor information

Editors and Affiliations

  1. Dept. of Physiology and Pharmacology, Sapienza University, Rome, Italy

    Patrizia Campolongo

  2. Institute of Neuroscience CNR, University of Cagliari, Cagliari, Italy

    Liana Fattore

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Miller, M., Chadwick, B., Morris, C., Michaelides, M., Hurd, Y. (2015). Cannabinoid-Opioid Interactions. In: Campolongo, P., Fattore, L. (eds) Cannabinoid Modulation of Emotion, Memory, and Motivation. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2294-9_15

Download citation

Publish with us

Policies and ethics

Search

Navigation